Advanced Enzyme Technologies Q2 FY27 Share Price & Earnings Call Analysis
Part of: Nifty Microcap 250 · Nifty Total Market
- Market cap
- ₹3,115 Cr
- P/E
- 19.16
- ROE
- 10.52%
- PEG
- 1.39
- Price to sales
- 3.99
- Debt to equity
- 0.03
- 52W high / low
- ₹392 / ₹248
- Sales growth (5Y)
- 8.24%
- EBITDA margin
- 30.40%
- Net profit margin
- 22.15%
- Promoter holding
- 43.56%
- Sales (last year)
- ₹782 Cr
Advanced Enzyme Technologies Limited is engaged in the business of manufacturing and sales of enzymes.[1]
Guidance scorecard · Q2 FY27 call
What Advanced Enzyme's management guided
and where it ranks in Pharmaceuticals & Biotechnology
Pharmaceuticals & Biotechnology
RevenueQ2 FY27 call
10–20%- Company expects overall growth at a mid to lower mid double-digit rate over the longer term (FY27 and FY28).
- Budgeting and more specific outlook expected by Feb-Mar next year.
- Sustained strong growth anticipated across all segments including Human Healthcare, Animal Healthcare, Bio-Processing, and Specialized Manufacturing.
- U.S. market shows signs of turnaround with expected pickup towards year-end, which could positively impact growth.
- Growth driven by a combination of new customers, new products, and expanding geographies.
- SciTech (Specialized Manufacturing) segment showing robust traction with broad-based customer growth.
2 more points from Advanced Enzyme's call on revenue
Create a free account to keep reading this call
MarginsQ2 FY27 call
FlatSee what Advanced Enzyme said on margins — free account, 30 seconds.
CapexQ2 FY27 call
Planned- Capex guidance for FY27 remains at approximately INR123 crores, which includes R&D and maintenance capex.
- Around INR52 crores of this capex has already been spent in H1 of FY27.
- The company continues to invest in R&D, new product development, and sales team strengthening.
- There is an emphasis on operational efficiencies and expanding production capacity, e.g., at SciTech with shift improvements.
FundraisingQ2 FY27 call
See what Advanced Enzyme said on fundraising — free account, 30 seconds.
Order bookQ2 FY27 call
Ask what Advanced Enzyme said on the order book →
Full Q2 FY27 analysisRanges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹480 Cr | 19.1 | |
| 2 | 40%+ | Up 0–2% | ₹212 Cr | 16.1 | |
| 3 | 40%+ | Flat | ₹18,347 Cr | — | |
| 4 | 40%+ | Flat | ₹8,418 Cr | 32.3 | |
| 5 | 40%+ | Flat | ₹4,268 Cr | — | |
| 6 | 40%+ | Flat | ₹40 Cr | — |
Sign up free to see every company in the sector ranking and track Advanced Enzyme.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingFinancials of Advanced Enzyme
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Shareholder Pattern
Advanced Enzyme
Shareholding breakup across reporting periods.
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters + | 43.62% | 43.50% | 43.02% | 42.95% | 42.92% | 43.08% | 43.08% | 43.08% | 43.04% | 43.26% | 43.25% | 43.56% |
| FIIs + | 22.54% | 23.01% | 12.03% | 12.63% | 12.57% | 11.90% | 23.45% | 25.41% | 25.85% | 25.50% | 26.70% | 26.64% |
| DIIs + | 6.98% | 7.56% | 8.08% | 8.02% | 8.17% | 8.19% | 8.45% | 6.41% | 5.51% | 5.41% | 4.77% | 1.89% |
| Public + | 26.88% | 25.95% | 36.87% | 36.40% | 36.31% | 36.82% | 25.00% | 25.09% | 25.62% | 25.85% | 25.28% | 27.90% |
| No. of Shareholders | 73,034 | 68,640 | 65,222 | 66,758 | 67,351 | 65,322 | 67,589 | 69,637 | 68,051 | 66,193 | 63,599 | 67,468 |
Financials of Advanced Enzyme
Quarterly Results
Quarter-by-quarter operating performance
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 158 | 161 | 158 | 155 | 146 | 169 | 167 | 186 | 185 | 172 | 203 | 192 | 215 |
| YoY Sales growth | +14% | +13% | +14% | +5% | -7% | +5% | +6% | +20% | +26% | +2% | +22% | +3% | +16% |
| Expenses + | 107 | 107 | 102 | 103 | 104 | 114 | 122 | 129 | 124 | 123 | 140 | 139 | 142 |
| Operating Profit | 51 | 54 | 55 | 51 | 42 | 55 | 46 | 56 | 60 | 49 | 63 | 53 | 72 |
| OPM % | 32% | 33% | 35% | 33% | 29% | 33% | 27% | 30% | 33% | 29% | 31% | 28% | 34% |
| Other Income + | 6 | 14 | -6 | 7 | 10 | 8 | 9 | 9 | 10 | 20 | 7 | 11 | 9 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 9 | 9 | 9 | 9 | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 10 | 11 |
| Profit before tax | 48 | 59 | 40 | 49 | 42 | 53 | 43 | 55 | 60 | 58 | 60 | 54 | 69 |
| Tax % | 27% | 28% | 25% | 28% | 21% | 27% | 38% | 26% | 25% | 26% | 24% | 28% | 26% |
| Net Profit + | 35 | 42 | 30 | 35 | 33 | 39 | 27 | 40 | 45 | 43 | 45 | 39 | 51 |
| EPS in Rs | 3.08 | 3.74 | 2.53 | 3.05 | 2.94 | 3.37 | 2.37 | 3.57 | 3.87 | 3.80 | 3.84 | 3.31 | 4.31 |
Financials of Advanced Enzyme
Profit & Loss
Annual income statement trend
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 222 | 293 | 329 | 391 | 420 | 444 | 502 | 529 | 541 | 624 | 637 | 746 | 782 |
| Sales growth | -7% | +32% | +12% | +19% | +7% | +6% | +13% | +5% | +2% | +15% | +2% | +17% | +11% |
| Expenses + | 131 | 155 | 177 | 226 | 236 | 241 | 269 | 327 | 382 | 418 | 441 | 515 | 544 |
| Operating Profit | 91 | 138 | 152 | 165 | 184 | 203 | 232 | 203 | 158 | 206 | 196 | 230 | 238 |
| OPM % | 41% | 47% | 46% | 42% | 44% | 46% | 46% | 38% | 29% | 33% | 31% | 31% | 30% |
| Other Income + | 1 | -3 | 3 | 1 | 5 | 6 | 9 | 6 | 21 | 21 | 33 | 46 | 47 |
| Interest | 9 | 8 | 4 | 9 | 5 | 4 | 3 | 3 | 3 | 4 | 5 | 4 | 3 |
| Depreciation | 9 | 9 | 13 | 18 | 21 | 26 | 28 | 35 | 35 | 35 | 37 | 40 | 41 |
| Profit before tax | 74 | 118 | 137 | 139 | 162 | 179 | 210 | 171 | 140 | 188 | 187 | 233 | 240 |
| Tax % | 31% | 35% | 32% | 33% | 28% | 26% | 28% | 28% | 26% | 27% | 28% | 25% | |
| Net Profit + | 51 | 77 | 93 | 94 | 116 | 133 | 151 | 124 | 104 | 137 | 134 | 174 | 178 |
| EPS in Rs | 4.60 | 6.97 | 8.20 | 8.07 | 9.95 | 11.58 | 13.09 | 10.70 | 9.45 | 11.92 | 11.72 | 15.07 | 15.26 |
| Dividend Payout % | 4% | 3% | 5% | 6% | 6% | 5% | 7% | 9% | 11% | 43% | 44% | 36% |
Financials of Advanced Enzyme
Balance Sheet
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 |
| Reserves | 188 | 256 | 442 | 537 | 657 | 817 | 948 | 1,066 | 1,213 | 1,302 | 1,398 | 1,610 | 1,643 |
| Borrowings + | 115 | 101 | 54 | 67 | 35 | 28 | 23 | 35 | 34 | 47 | 39 | 32 | 54 |
| Other Liabilities + | 92 | 71 | 65 | 102 | 91 | 104 | 153 | 137 | 142 | 150 | 151 | 170 | 187 |
| Total Liabilities | 417 | 450 | 583 | 727 | 805 | 971 | 1,146 | 1,260 | 1,411 | 1,521 | 1,611 | 1,834 | 1,906 |
| Fixed Assets + | 287 | 285 | 421 | 491 | 495 | 563 | 601 | 619 | 649 | 650 | 679 | 692 | 724 |
| CWIP | 5 | 7 | 8 | 11 | 10 | 10 | 10 | 15 | 22 | 41 | 22 | 51 | 83 |
| Investments | 0 | 0 | 0 | 0 | 111 | 124 | 121 | 102 | 360 | 403 | 480 | 584 | 488 |
| Other Assets + | 125 | 158 | 153 | 226 | 188 | 275 | 413 | 524 | 380 | 427 | 430 | 507 | 610 |
| Total Assets | 417 | 450 | 583 | 727 | 805 | 971 | 1,146 | 1,260 | 1,411 | 1,521 | 1,611 | 1,834 | 1,906 |
Financials of Advanced Enzyme
Cash Flows
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 54 | 93 | 107 | 116 | 129 | 141 | 163 | 122 | 140 | 141 | 142 | 157 |
| Cash from Investing Activity + | -15 | -10 | -60 | -60 | -124 | -43 | -27 | 2 | -286 | -65 | -89 | -72 |
| Cash from Financing Activity + | -36 | -63 | -65 | -2 | -43 | -39 | -26 | -48 | -26 | -59 | -73 | -70 |
| Net Cash Flow | 2 | 21 | -18 | 54 | -38 | 60 | 109 | 75 | -171 | 17 | -20 | 15 |
| Free Cash Flow | 42 | 88 | 97 | 105 | 116 | 90 | 143 | 95 | 102 | 94 | 108 | 105 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 88% | 88% | 105% | 97% | 70% | 94% | 94% | 87% | 112% | 93% | 103% | 96% |
Financials of Advanced Enzyme
Ratios
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 61 | 52 | 55 | 55 | 51 | 61 | 63 | 61 | 68 | 58 | 66 | 71 |
| Inventory Days | 403 | 358 | 352 | 339 | 363 | 361 | 346 | 402 | 343 | 375 | 378 | 335 |
| Days Payable | 89 | 68 | 57 | 78 | 46 | 43 | 56 | 60 | 67 | 40 | 47 | 76 |
| Cash Conversion Cycle | 374 | 342 | 351 | 315 | 369 | 379 | 353 | 404 | 344 | 393 | 397 | 331 |
| Working Capital Days | -43 | 3 | 76 | 47 | 72 | 90 | 94 | 116 | 109 | 102 | 112 | 116 |
| ROCE % | 25% | 36% | 31% | 25% | 24% | 22% | 22% | 16% | 12% | 15% | 13% | 14% |
Guidance history
How Advanced Enzyme's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q2 FY27 call → | 10–20% | Flat | Planned | — | — |
| Q1 FY27 call → | 10–20% | Flat | Planned | — | Rising |
| Q4 FY26 call → | 10–20% | Flat | Planned | — | Rising |
| Q3 FY26 call → | 10–20% | Flat | Planned | — | — |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Momentum score · price trend
15 out of 100 — Cooling
Over the past year its share price has done worse than most of the stocks we track.
| Period | Share price change | Better than … of 1,920 stocks |
|---|---|---|
| Last 12 months | −9.9% | 44% |
| Last 6 months | −21.5% | 18% |
| Last 3 months | −13.6% | 29% |
The price is 47.9% below its all-time high of ₹538.05 (20 Sept 2024). Stocks more than 20% below their peak have their score halved, so 30 became 15.
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,920 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Advanced Enzyme: 0.4 × 44 + 0.4 × 18 + 0.2 × 29 = 30, halved to 15 because the price is more than 20% below its all-time high.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 6 Nov 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.
Continue your research
What Advanced Enzyme's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Divis Laboratories (Q2 FY27)
Consolidated total income: ₹3770 crores . Key results statement takeaways from Divis Laboratories Ltd's Q2 FY27 results statement — and how it ranks against sec
- Infinium Pharma (Q2 FY27)
3,940.98 Lacs (about 54.3% increase) . Key results statement takeaways from Infinium Pharmachem Ltd's Q2 FY27 results statement — and how it ranks against secto
- Walpar Nutrition (Q2 FY27)
3,631.14 Lakhs for the half year ended September 30, 2025, reflecting a year-on-year increase of approximately 13.79%. Key results statement takeaways from Walp
- Kilitch Drugs (Q2 FY27)
14.3%) . Key results statement takeaways from Kilitch Drugs (India) Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
